According to Fortune Business Insights, The global dermal fillers market is projected to grow from USD 5.31 billion in 2022 to USD 8.74 billion by 2029, exhibiting a CAGR of 7.4% during the forecast period. Surge in Demand for Negligibly Invasive Cosmetic Processes to Encourage Market Growth
Pune, India, May 11, 2022 (GLOBE NEWSWIRE) -- The global dermal fillers market size was valued at USD 5.05 billion in 2021. The market is projected to grow from USD 5.31 billion in 2022 to USD 8.74 billion by 2029, exhibiting a CAGR of 7.4% during the forecast period. This information is published by Fortune Business Insights, in its report titled, “Dermal Fillers Market, 2022-2029.”
February 2021: Allergan Aesthetica and CollPlant conjointly declared the development and global commercial contract to utilize their plant derived recombinant human collagen (rhCollagen) with Allergan’s proprietary technology to improve and commercialize dermal and soft tissue fillers.
https://www.fortunebusinessinsights.com/enquiry/sample/dermal-fillers-market-100939
Dermal Fillers Market Report Scope & Segmentation :
By Material, Application, Product, End User
Surge in Demand for Negligibly Invasive Cosmetic Processes to Encourage Market Growth
Sinclair Pharma Presents Novel HA Filler to Boost its Revenue Prospects
Surging R&D Initiatives Pooled with Growing Demand for Dermal Fillers Processes to Trigger Growth
Termination of Elective Cosmetic Surgeries to Adversely Influence the Market amid COVID-19
The effect of COVID-19 was noticeable in the healthcare sector as it was at the center of this unparalleled global pandemic event. The market has been predominantly influenced as it is measured as an optional procedure and was among one of the prime medical courses to be hit by eliminations. Chief corporations perceived a deterioration in their revenue in 2020 in comparison with the previous year as elective and non-crucial processes were considerably hindered in numerous nations.
Based on material, the global market is segmented into hyaluronic acid, calcium hydroxylapatite, Poly-L-Lactic Acid (PLLA), PMMA (Poly (Methyl Methacrylate)), fat fillers, and others. The hyaluronic acid (HA) segment emerged as the dominant segment in 2021, owing to its status as a gold standard for dermal fillers.
On the basis of product, the market is segmented into biodegradable and non-biodegradable.
On the basis of application, the market is segmented into scar treatment, wrinkle correction treatment, lip enhancement, restoration of volume/fullness, and others.
Based on end-user, the market is segmented into specialty & dermatology clinics, hospitals & clinics, and others.
On the basis of region, the market is segmented into North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa.
To get to know more about the short-term and long-term impact of COVID-19 on this market, please visit:
https://www.fortunebusinessinsights.com/industry-reports/dermal-fillers-market-100939
The report presents a comprehensive review of the market and a strong examination of the major segments of the market. It delivers an in-depth analysis of prime players and their insightful tactics to boost the dermal fillers market growth for monetary gains. It also shares tangible insights that guide business owners with their investment standpoint. The regional dynamics is also accessible in the report.
Surge in Demand for Negligibly Invasive Cosmetic Processes to Encourage Market Growth
One of the most crucial market driving factors toward the global market growth is the considerable upsurge in demand for facial aesthetics. Individuals have sought stress-free and moderately painless surgeries for a youthful presence and healthy appearance in recent years. Meanwhile, invasive cosmetic surgeries frequently have numerous consequences and often require the patient to take additional days for recovery.
However, the high cost linked with these products is one of the prime obstacles contributing to the deterioration of the growth of the market.
https://www.fortunebusinessinsights.com/enquiry/speak-to-analyst/dermal-fillers-market-100939
North America to Lead Stoked by Financially Steady Economy
North America is expected to dominate throughout the forecast period. The region is also anticipated to hold the dominant dermal fillers market share during the forecast period. A few of the aspects for the domination of this region comprise of a greatly conscious and financially steady population.
Europe is predicted to hold the second highest market share, which is accredited to the growing inclination amongst individuals for experiencing dermal filler processes in important European nations and increasing expenditure on R&D in Europe.
Asia Pacific is projected to perceive the greatest growth rate during the forecast period. The enhancement in healthcare infrastructure in Asian nations, surging aging population, and the growing awareness of individuals concerning their physical presence are fueling the market growth in the region.
Chief Business-related Proclamations by Key Players to Boost the Market
Chief corporations in the market often make vital announcements about their key strategies, which, in turn, positively impact the market. Players purchase corporations, launch new products, engage in partnership contracts, sign agreements with organizations, and others.
List of Key Players Mentioned in the Report:
ALLERGAN (AbbVie, Inc.) (U.S.)
Revance Therapeutics, Inc. (U.S.)
BIOPLUS CO., LTD. (South Korea)
SCULPT Luxury Dermal Fillers LTD (Czech Republic)
Anika Therapeutics, Inc. (U.S.)
Quick Buy - Dermal Fillers Market Research Report:
https://www.fortunebusinessinsights.com/checkout-page/100939
Overview of the Number of Dermal Fillers Procedures by Key Countries
Overview of Price Analysis of Types of Dermal Fillers
Overview of Regulatory Scenario by Key Countries
Overview of Reimbursement Scenario by Key Countries
Impact of COVID-19 on Dermal Fillers Market
Global Dermal Fillers Market Analysis, Insights and Forecast, 2018-2029
Market Analysis, Insights and Forecast – By Material
Market Analysis, Insights and Forecast – By Product
Market Analysis, Insights and Forecast – By Application
Market Analysis, Insights and Forecast – By End User
Market Analysis, Insights and Forecast – By Region
North America Dermal Fillers Market Analysis, Insights and Forecast, 2018-2029
Market Analysis, Insights and Forecast – By Material
Market Analysis, Insights and Forecast – By Product
Market Analysis, Insights and Forecast – By Application
Market Analysis, Insights and Forecast – By End User
Market Analysis, Insights and Forecast – By Country
Ask for Customization of this Report:
https://www.fortunebusinessinsights.com/enquiry/customization/dermal-fillers-market-100939
Fortune Business Insights™ delivers accurate data and innovative corporate analysis, helping organizations of all sizes make appropriate decisions. We tailor novel solutions for our clients, assisting them to address various challenges distinct to their businesses. Our aim is to empower them with holistic market intelligence, providing a granular overview of the market they are operating in.
Fortune Business Insights Pvt. Ltd.9th Floor, Icon Tower, Baner –
Read Press Release:https://www.fortunebusinessinsights.com/press-release/dermal-fillers-market-9173
Shares of the artificial intelligence lender Upstart Holdings (NASDAQ: UPST) traded more than 16% lower as of 11:14 a.m. ET today after it received yet another downgrade from Wall Street. Wedbush analyst David Chiaverini maintained his underperform rating on Upstart but lowered his price target from $20 to $15 per share. The lower price target comes just a week after Chiaverini lowered his price target on Upstart from $35 to $20.
When Berkshire Hathaway (NYSE: BRK.A)(NYSE: BRK.B) CEO Warren Buffett buys or sells shares of a company, Wall Street and investors tend to pay close attention. Since becoming CEO in 1965, he's overseen the creation of more than $680 billion in shareholder value and delivered an average annual return of 20.1% for Berkshire's Class A (BRK.A) shareholders (himself included).
An earnings recession is not the biggest threat facing the stock market right now. To show that an earnings recession doesn’t necessarily doom the stock market, consider the S&P 500’s (SPX) quarterly return when its earnings-per-share (EPS) is falling. On average over the past century, according to an analysis conducted by Ned Davis Research, the S&P 500 has performed better when its EPS were lower than a year previously — not higher.
Shares of Nvidia (NASDAQ: NVDA) continued to tumble on Friday, falling as much as 8%. Wells Fargo analyst Aaron Rakers lowered his price target on Nvidia to $250, down from $370, while maintaining his overweight (buy) rating on the stock, according to The Fly.
Shares of Pfizer (NYSE: PFE) were up 2.5% as of 11:35 a.m. ET on Friday after jumping as much as 4% earlier in the day. Meanwhile, the stocks of two other COVID-19 vaccine makers were declining. Moderna's (NASDAQ: MRNA) shares were down 4.7%.
Cathie Wood is a long-time Tesla bull, but the stock isn't the largest holding in Wood's ARK Innovation ETF anymore.
In this article, we discuss 6 stocks that Warren Buffett is selling in 2022. If you want to see more stocks that the billionaire sold, click Warren Buffett is Selling These 3 Stocks in 2022. Warren Buffett, the chief of Berkshire Hathaway, is perhaps the most renowned financier in the investment world, with decades of […]
The Dow Jones reversed higher while the S&P 500 battled out of bear market territory. Tesla stock dived amid reports about CEO Elon Musk.
Shares of the e-commerce platform company Shopify (NYSE: SHOP) were plunging today just one day after its share price soared by double digits. Today's drop was caused by ongoing fears about high inflation and upcoming Federal Reserve interest rate hikes. As a result, the tech-heavy Nasdaq Composite had slid 2.5% and Shopify's stock had tumbled 10.8% as of 2:44 p.m. ET.
In this article, we discuss 10 buy-the-dip stocks to buy according to billionaire Ken Fisher. If you want to skip our detailed analysis of Fisher’s stock selection and the current sell-off in tech, go directly to 5 Best Buy-the-Dip Tech Stocks According to Billionaire Ken Fisher. The tech-heavy Nasdaq Composite is down 27% in 2022 […]
Yahoo Finance Live anchors discuss second-quarter earnings for Deere.
In early trading Friday, stock markets attempted to make a comeback and at least end a losing week on a winning note. As of 12:25 p.m. ET, shares of Rivian Automotive (NASDAQ: RIVN) are off 4.9%, Nikola (NASDAQ: NKLA) stock is down 5.8%, and Lucid Group (NASDAQ: LCID) -- the beneficiary of positive news as recently as yesterday -- is giving back most of its gains, and leading the sector 6.8% lower today.
In early trading Friday, stock markets attempted to make a comeback and end a down week on an up note. As The Fly reports, Truist has only a neutral rating on each of Royal Caribbean and Norwegian Cruise Line -- and rates Carnival stock an out and out sell.
(Bloomberg) -- It’s been hard to watch, impossible to predict and a nightmare to trade. But has the S&P 500’s slide been an unqualified panic to date? By some measures no, and that might bode poorly for equities in the near term. Most Read from BloombergOne of the World’s Frothiest Housing Markets Turned Into a Seller’s Headache OvernightElon Musk Gets Defensive Over Twitter Meme as Harassment Report SurfacesApple Shows AR/VR Headset to Board in Sign of Progress on Key Project Stocks Avert Bear
Nio (NYSE: NIO) shares began trading on the main board of the Singapore stock exchange today prior to the opening of the U.S. markets. After initially popping 20% early, the new shares ended up closing in Singapore about 2.4% higher, according to Barron's.
Investors weren't overjoyed about a fresh debt offering announced by Carnival, and a bearish new note from an analyst didn't help, either. After market hours on Wednesday, Carnival announced that it is floating a private offering of $1 billion worth of senior unsecured notes. Carnival says it plans to use the net proceeds of the issue to make scheduled principal payments on debt during fiscal 2023 and for general corporate purposes.
In this article, we discuss 10 financial stocks that Warren Buffett is buying in 2022. If you want to see more financial stock picks of the billionaire, click Warren Buffett is Buying and Holding These 5 Financial Stocks in 2022. Warren Buffett follows the Benjamin Graham school of thought, picking value plays with prices that […]
Rising interest rates, supply chain constraints and Russia’s invasion of Ukraine are all issues currently plaguing the macro climate. The problem with all three, says Tony Dwyer, Canaccord Chief Market Strategist, is that for each problem there’s “no easy exit strategy.” The tough conditions are likely to persist, then. However, on the plus side, while these issues have sent most corners of the stock market into a tailspin, now investors are presented with stocks for which the term “oversold” re
Like many tech and fintech stocks this year, the Berkshire Hathaway-backed Brazilian digital bank Nu Holdings (NYSE: NU) has seen its stock price struggle and is down more than 61% this year. Nu is a major disruptor in the Latin American banking space, first offering a credit card with no annual fees and then building out a suite of banking products from there. Nu has amassed close to 60 million customers but in the past has gotten questions regarding its high valuation and path to sustainable profitability.
In this article, we discuss Michael Burry’s short position in Apple Inc. (NASDAQ:AAPL) and the 5 stocks he is selling in 2022. If you want to skip our analysis of Burry’s history, investment philosophy, and hedge fund performance, go directly to Michael Burry Is Selling These 3 Stocks in 2022. Michael Burry was born on […]